Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
About this item
Full title
Author / Creator
Edan, G , Kappos, L , Montalbán, X , Polman, C H , Freedman, M S , Hartung, H-P , Miller, D , Barkhof, F , Herrmann, J , Lanius, V , Stemper, B , Pohl, C , Sandbrink, R , Pleimes, D , for the BENEFIT Study Group and BENEFIT Study Group
Publisher
England: BMJ Publishing Group LTD
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group LTD
Subjects
More information
Scope and Contents
Contents
Objective To examine the long-term impact of early treatment initiation of interferon beta-1b (IFNB1b, Betaferon/Betaseron) in patients with a first event suggestive of multiple sclerosis (MS). Methods In the original placebo-controlled phase of BENEFIT, patients were randomised to IFNB1b 250 μg or placebo subcutaneously every other day. After 2 ye...
Alternative Titles
Full title
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4215285
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4215285
Other Identifiers
ISSN
0022-3050
E-ISSN
1468-330X
DOI
10.1136/jnnp-2013-306222
